December 2022 – Page 9 – schizophrenia

Dec 19 2022

Cerevel Therapeutics Announces Publication in The Lancetof Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia

by Clinical Editor

No Comments

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration. Data show clinically meaningful and statistically significant …

Dec 19 2022

Uncategorized

Fingerprint Images Have Potential for Predicting Schizophrenia

by Clinical Editor

No Comments

Fingerprint images have potential as predictors of schizophrenia, according to a study published online Nov. 29 in Schizophrenia Bulletin.

Dec 18 2022

Uncategorized

A better way to help New Yorkers with mental illnesses – New York Daily News

by Clinical Editor

No Comments

A better way to help New Yorkers with mental illnesses New York Daily News

Dec 18 2022

Uncategorized

Childhood chronic conditions up with maternal schizophrenia – Medical Xpress

by Clinical Editor

No Comments

Childhood chronic conditions up with maternal schizophrenia Medical Xpress

Dec 18 2022

Uncategorized

Why Is Stigma Toward Schizophrenia Getting Worse?

by Clinical Editor

No Comments

Stigma toward schizophrenia may be linked to the increasing acceptance of biological explanations for it, rather than psychosocial ones. Reversing the trend will involve looking carefully at media …

Dec 18 2022

Uncategorized

Sleep Abnormalities in Schizophrenia Patients

by Clinical Editor

No Comments

Sleep abnormalities can occur in up to 80 percent of patients with schizophrenia spectrum disorders. Many biological and genetic factors contribute to this, including genes and circadian rhythms.

Dec 18 2022

Uncategorized

Childhood chronic conditions up with maternal schizophrenia

by Clinical Editor

No Comments

Children exposed to maternal schizophrenia have an increased risk for chronic health conditions in childhood, according to a study published in the November issue of Schizophrenia Bulletin.

Dec 18 2022

Uncategorized

Cerevel Therapeutics Announces Publication in The Lancetof Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia

by Clinical Editor

No Comments

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration. Data show clinically meaningful and statistically significant …

Dec 18 2022

Uncategorized